Cigna Group (CI) showed impressive performance with double-digit revenue growth in Q1 2024, raising its outlook for FY24. The biotech company's revenue surpassed market expectations, though the EPS slightly lagged. The steady growth caused Oppenheimer and Cantor Fitzgerald to raise their price target to $400. Cigna also declared an increased $1.40 dividend and a $3.2 billion accelerated stock repurchase. Innovation was evident with the introduction of new plans for globally mobile seniors and a grant program addressing youth mental health. AM Best affirmed Cigna's credit ratings, indicating a robust financial situation. Finally, Cigna announced the sale of its Medicare Businesses and CareAllies to HCSC.
The Cigna Group CI News Analytics from Wed, 25 Oct 2023 07:00:00 GMT to Thu, 09 May 2024 11:07:19 GMT -
Rating 7
- Innovation 6
- Information 9
- Rumor -4
